Microsoft word - cardio.2006.doc

Annual Report
Division of Cardiology
April 1, 2005 - March 31, 2006

1. Highlights - April 1, 2005 - March 31, 2006
Despite severe constraints in staffing and other budgetary issues, the Division has been extremely
active during the past year. Clinic activities include:
CCU Admissions - 1197
2 Cardiac CTU Admissions - 1740
Pacemaker Clinic visits - 1700
Pacemaker Program - 359
Cardiology Clinic Visits - 631
Physician Consults - 2879
GFT Physician Visits - 7801
Diagnostic Cardiac Catheterizations - 1300
Coronary Angioplasties - 493
Primary Coronary Stenting - 146
Echocardiograms (including transepsophageal and stress echos) -7512
Electrocardiograms - 17269
Holter monitorings - 682
Ambulatory BP monitorings - 308
Exercise stress tests (including Dobutamine echos) -899
Cardiac stress nuclear imaging - 844
Our clinic and teaching programs continue to receive top ratings, and or research activity continues to
grow.
II. Evaluation of Past Academic Year - April 1, 2005 - March 31, 2006
Faculty -
We are delighted that Dr Regina Husa has joined the Division. Regina is a gifted clinical cardiologist,
with particular expertise in cardiac critical care. Her academic interests focus on the teaching of
cardiology, and assessment of effectiveness of teaching techniques. She has assumed the role of CTU
director for cardiology. Dr Husa will be obtaining her Masters degree in Education from Harvard
University in 2007.
After a long distinguished career as director of our Hemodynamic Laboratory, Dr Leonidas Dragatakis
has resigned that position and will continue in the Division as a valued clinician. Dr. Robert
Schlesinger has been appointed director of the hemodynamic labs.
Clinical Activities -
In addition to the individual clinics each doctor holds, the Division also holds a Pacemaker Clinic on
Friday mornings, Cardiology Clinic on Friday mornings, Adult Congenital Clinic on Wednesday
mornings, and a Pulmonary Vascular Disease Clinic on Mondays. Our extremely active Congestive
Heart Failure Clinic under the leadership of Dr Caroline Michel and Dr Richard Sheppard, provides
Monday to Friday service for CHF patients, reducing Emergency Room visits and hospitalizations.
Honours and Awards (June 1, 2005 - May 31, 2006)
MARK EISENBERG MD
Tenure: Associate Professor McGill University Faculty of Medicine
GEORGE HONOS MD
Director of echocardiography and noninvasive Cardiology Jewish General Hospital. July 1989 -.
Treasurer, Canadian Cardiovascular Society. 2001 - 2006
Chair, Cardiology Examinations Board, Royal College of Physicians and Surgeons of Canada. 2005 -
2010.
Heart and Stroke Foundation of Canada Specialist spokesperson. 2002 - present.
Heart and Stroke Foundation of Quebec Specialist spokesperson. 2002 - present.
President, Echocardiography Society. 1994 - present

DAVID LANGLEBEN MD
Teacher of the year, Dept. of Medicine, JGH, June 2005
Scientific Leadership Council, Pulmonary Hypertension Association (USA), 2005-2006
CAROLINE MICHEL MD
Appointed to “Ventricular Assist Device Committee”. Jewish General Hospital
Appointed to “McGill University Heart Transplant Multidisciplinary Committee”. MUHC, McGill
University

IGAL SEBAG MD
Editor for Cardiology, Canadian Journal of Diagnosis

JUDITH THERRIEN MD
President of the CACH (Canadian Adult Congenital Heart) network. 2005 - 2007
Heart and Stroke Foundation Research Scholars Award, Salary Support. 2001-2006.
ANN WALLING MD
Promoted to Associate Professor of Medicine
Teaching Activities
LEONIDAS DRAGATAKIS MD
- Courses lectured - Hemodynamics for McGill Cardiology Fellows
- EKG: Introduction to Clinical Medicine
- total number of lecture hours: 21
- Clinical Teaching Hours. CTU - 120, Consults - 232
MARK EISENBERG MD
- Small group on palpitations. Department of Medicine. 2.5 hours/year
- Cardiovascular Journal Club Meeting host for Internal Medicine Fellows. Department of Medicine.
10 hours/year - Journal Club Meeting host for Internal Medicine Residents. Department of Medicine. 10 hours/year - Coordinator, “Epidemiology Evenings” McGill University. Cardiology Fellows. 40 hours/year - Cardiac Catheterization Laboratories (> 160 hrs/year) - Cardiology Fellows - Cardiac Care Unit (>140 hours/year). Cardiology Fellows, Residents, Medical Students - Consultations (>120 hours/year). Cardiology Fellows, Residents, Medical Students - Research Trainees Supervised - - Robert Maranda MD

GEORGE HONOS MD
McGill Cardiology Training Program/Echocardiography0 continuous training of Fellows (year 1-3)all
year round, Post-doctoral echo Fellows trained:

CCU/ward round/Consult service teaching- 12 weeks/year
Echo Lab teaching of Cardiology Fellows - equivalent of 15 full weeks/year
McGill occupational therapy-Cycle 2- one 3 hour lecture on cardiovascular disease. September 2005
McGill Echo Rounds: “Diagnosis of pericardial constriction by echocardiography”

DAVID LANGLEBEN MD
-Total clinical teaching CCU - 8 weeks, Consults - 8 weeks
- Teaching of Cardiology Fellows in the Pulmonary Hypertension Clinics
- IIM (ICMB) - April 2006
- Respiratory Rounds. Hotel Dieu. “Consensus Canadien sur l’Hypertension Pulmonaire
Pathophysiologie et Traitement”. August 2005
- McGill Anesthesia Update. Invited speaker. “ Pulmonary Hypertension- Anesthetic Considerations”
May , 2006.
- Hopital Charles LeMoyne. Invited speaker. “L’Hypertension Pulmonaire: Nouvelle classification,
investigation et therapie”. September 2005
CAROLINE MICHEL MD
- Continuous training of Cardiology Fellows
- Post doctoral echocardiography Fellows trained:
Dr
- Total clinical teaching. CCU - 4 weeks, Consults - 5 weeks
- Teaching of Cardiology Fellows: Peripartum Cardiomyopathy
- Quebec Heart Failure Society: Small Group sessions moderator. April 2006
- Quebec Heart Failure Society: Small Group Sessions Moderator and presentation “Quebec Heart
Failure Network. September 2005
IGAL SEBAG MD
- Professional Skills (ICM-A), McGill Medical School Program.
- Introduction to Internal Medicine (ICM-B), McGill Medical School Program. Chest pain and
Palpitations.
- Physical Examination Skills at the Bedside, McGill Internal Medicine Training Program.
- Number of post-doctoral fellows: 3 Echocardiography Fellows
- Total clinical teaching hours. CTU - 5 weeks, Consults - 5 weeks
- Lecture. McGill Cardiology Academic Rounds, McGill Training Program. Prosthetic heart valves.
December 2005
- Lecture. Jewish General Hospital Echocardiography Rounds. “Three Dimensional Assessment of
Mitral Stenosis: A Review” December 2005
- Lecture. McGill Echocardiography Rounds, McGill Cardiology Training Program. “Mitral Stenosis”
December 2005
- Lecture. Cardiovascular Surgeons, Echocardiographers and Anaesthesiologists. “Cardiovascular
Imaging and Surgery Rounds: Acute Surgical reperfusion in Acute MI. June 2005.
- Lecture. McGill Echocardiography Rounds, McGill Cardiology Training Program. “Aortic Stenosis”.
November 2005
- Lecture. Jewish General Hospital Echocardiography Rounds. “Real-time, three-dimensional,
dobutamine stress echocardiography”. November 2005
- Lecture. McGill Cardiology Academic Rounds, McGill Cardiology Training Program. “Mechanical
complications of acute myocardial infarction”, November 2005
RICHARD SHEPPARD MD
-Total clinical teaching CCU - 6 weeks, Consults 7 weeks
- Journal club (heart failure) April 2005
- Lecture (heart failure) Cardiology Fellows March 2006
- Lecture (heart failure) Cardiology Fellows April 2006
- Lecture (chest pain) Medical Students. June 2005.
JUDITH THERRIEN MD
- Total clinical teaching CCU - 5 weeks, Consults - 3 weeks

ANN WALLING MD
-Courses Coordinated: Organized and coordinated the second annual R5 provincial OSCE Royal
College preparatory exam in November 2005. This recruited all the R5 candidates in the 4 teaching
universities across the province. It was held at the JGH over 1 day.
- Organized the first STACER exam for R5 Cardiology Fellows. This is a new mandatory exam to
assess the physical exam skills of the residents prior to taking the final Royal college exams in Ottawa.
- POM examiner - 3 hours
-ECG course 2nd year medical students - 3 hours
- Post doctoral fellows trained: 1 year -
CTU - 144 hours (2 hrs/day, 12 days - 6 weeks) Consults - 60 hours (2 hrs/day, 5 days 6 weeks) Echo lab - Continuous training of Fellows (year 1 - 3) all year round Echo lab teaching of Cardiology Fellow (equivalent of 15 full weeks/yr) - CME courses: 100 hours - wrote and corrected three 2 hour exams with SAQ for Cardiology
Residents
- Organized the OSC R5 day - 20 hours
- Organized the STACER exam - 10 hours
- “Coached” residents for ACE academic contest a provincial competition for Cardiology Residents
competing for their universities - 6 hours

Service to Academic Community and other Contributions

LEONIDAS DRAGATAKIS MD
Member, Organizing Committee for 2005 Annual Scientific Meeting of Association of Cardiologists of
Quebec
MARK EISENBERG MD
Journals
Editorial Boards:
Canadian Journal of Diagnosis
American Journal of Cardiology
Journal of the American College of Cardiology
Cardiosource Clinical Trials Editorial Board
Journal of the Asian Federation of Cardiology
Perspectives in Cardiology
Ad Hoc Reviews:
American Heart Journal
American Journal of Cardiology
American Journal of Medicine
Archives of Internal Medicine
Canadian Journal of Cardiology
Canadian Medical Association Journal
Circulation
Heart
Journal of the American College of Cardiology - Named An “Elite Reviewer”
Journal of the American Medical Association
Journal of Cardiac Failure
Journal of Cardiovascular Pharmacology
Lancet
Medical Care
New England Journal of Medicine
Grant Reviews
Panel Member:
2006 - Quebec Foundation for Health Research, Physician-Scientist Salary Award Committee (5
days/year)
Ad hoc reviews:
Agency for Healthcare Research and Quality (AHRQ)
Alberta Heritage Foundation for Medical Research
American Board of Internal Medicine: Relevance Reviewer Interventional Cardiology
American Heart Association: 2005 Scientific Sessions Abstract Reviewer
British Columbia Health Research Foundation
Canadian Institutes of Health Research (CIHR)
Canadian Coordinating Office for Health Technology Assessment (CCOHTA)
Fonds de la Recherche en Sante du Quebec (FRSQ) Quebec Foundation for Health Research
Heart and Stroke Foundation of Canada (HSFC)
Medical Research Council of Canada
Committees
2005 - Member of the Electron-Beam Computed Tomography Clinical expert Consensus Document
Writing Committee, American College of Cardiology.
2005 - Chair of the Steering Committee for the Safety of Transdermal Nicotine Use Immediately
following an Acute Coronary Syndrome (STADIA) Trial.
2005 - Member of the Task Force on Clinical Expert Consensus Documents, American College of
Cardiology.
2004 - Chair of the Steering Committee for the Post angiographic Rates Of abstinence with Multiple
Smoking Cessation aids (PROMISE) Trial Pilot study.
2004 - Chair of Steering Committee for the Zyban as an Effective Smoking Cessation Aid Trial.
Other Professional and Scientific Contributions
2005 - First Latin-American Forum on Panvascular Diseases, Mexico City, Mexico. Conference
presentation on smoking cessation after acute coronary syndrome.
2005 - Canadian Cardiovascular Society, Montreal . Co-Chair of the Clinical Trials Session
2005 - American College of Cardiology, Orlando Fl. Member of the Journal of American College of
Cardiology editorial board. Member of the Electron-Beam Tomography Clinical expert Consensus
Document Writing Committee. Member of the Task Force on Clinical expert Consensus Documents
Committee.
Invited Lectures, Talks and Presentations
2006 - “Role of Drugs in Tobacco Cessation”. International Symposium on Cardiovascular Diseases,
Stroke and Diabetes, New Delhi, India.
2006 - Pharmacotherapy for smoking cessation. Pulmonary rounds. Jewish General Hospital.
2005- Zyban as an effective smoking cessation aid in patients following MI. McGill University,
Inaugural ICE Team Meeting, Montreal QC
2005 - Anglo-Scandinavian cardiac outcomes trial (ASCOT). McGill University, Cardiology
Fellows Epidemiology Series.
2005 - Acute myocardial infarction: Give thrombolytics or transfer for percutaneous coronary
intervention? Royal Victoria Hospital Grand Rounds. Montreal.
2005 - Smoking cessation after acute coronary syndromes. First Latin-American Forum on
Panvascular Diseases, Mexico City, Mexico.
2005- Zyban as an effective smoking cessation aid in patients following an acute coronary syndrome.
Shaare Zedek Hospital, Jerusalem, Israel. Rambam Hospital, Haifa, Israel.
2005 - Acute myocardial infarction: Give thrombolytics or transfer for percutaneous coronary
intervention? Barry Memorial Hospital. Ormstown Quebec.

GEORGE HONOS MD
Specialist Spokesperson, Quebec and Canadian Heart and Stroke Foundations (press conferences, TV,
radio and printed news media work throughout the year)
- Invited speaker. “Role of angiotensin receptor blockers in cardiovascular disease”. Symposia in
Taipei, Karhcung and Haishung, Taiwan. May 2005.
-Invited speaker. “Update on the ASCOT Hypertension Trial”. CHUM Interhospital Grand Rounds,
Hotel Dieu Hospital Montreal. September 2005.
-Invited speaker. “Update on the ASCOT Hypertension Trial”. Cardiology Rounds. JGH. September
2005.
-Invited speaker. “Update on the ASCOT Hypertension Trial and 2005 ESC Highlights Hotel Vogue,
Montreal. September 2005.
-Invited speaker. “Management of Global and Cardiovascular Risk: Is the Polypill the Solution?” CCC
Annual Congress Symposium Montreal. October 2005.
-Invited speaker. “Angiotensin Modulation and Clinical Outcome: Are we On Target”. Medical Grand
Rounds, Royal Victoria Hospital. Montreal. February 2006.
Journal/Newsletter/CD-ROM Editor. Cardiology Rounds and Scientific Updates. St Michael’s
Hospital. French language translation editor of Cardiology, Metabolism, Nephrology and Critical Care
Scientific Updates. Snell Medical Communication. 1996 - present.
Advisory Boards- Merck Frosst Canada and Co

DAVID LANGLEBEN MD
1. Journals
Ad hoc reviewer for:
Am J Cardiol
Am J Physiol, Lung
Annals of Int Med
Circulation
European Heart Journal
European Respiratory Journal
J Appl Physiology
Microvascular Research
2. Grant Reviewer
Ad hoc reviewer for:
Canadian Institutes for Health Research
Heart and Stroke Foundation of Canada
3. Administrative responsibilities and Committees
McGill
- Member, Admissions Committee, Faculty of Medicine, 2001 -
- Member, Cardiology Training Program Committee, 2000 -
Jewish General Hospital
- Chief, Division of Cardiology, 1997 -
- CTU Director, CCU/2 Cardiac, 1999 - 2006
- Chair, Medical Records Committee, 1994 -
- Director, Pulmonary Hypertension Clinic and Center for Pulmonary Vascular Disease, 1986-
4. Other Professional and Scientific Contributions
Member, Diagnosis Committee, International Primary Pulmonary Hypertension Study (IPPHS)
Member, Scientific Steering Committee, “A Study of Terbogrel in Pulmonary Hypertension”
Member, Scientific Steering Committee, “The Study of Pulmonary Hypertension in
America”(SOPHIA), Harvard School of Public Health
Member, Scientific Advisory Board, Pulmonary Hypertension Association (USA)
- Invited speaker. “Pathology and Mechanistic Targets of PAH”, Satellite Symposium, American
Thoracic Society Annual meeting, San Diego, May 2005.
- Invited speaker. “Oral Therapy for Pulmonary Arterial Hypertension: New Review”. Satellite
Symposium, CHEST 2005, Montreal November 2005.
- Invited speaker. “How and When To Decide Your Patient’s PAH therapy is nonoptimized”. Panel
discussion, CHEST 2005, Montreal November 2005.
CAROLINE MICHEL MD

- Member of Executive Committee, Quebec Heart Failure Society
- Member, Ventricular Assist Device Committee, Jewish General Hospital
- Member, McGill University Heart Transplant Multidisciplinary Committee
- Member of Finance Committee, JGH Cardiology GFT Cardiology Group
- Administrative responsibilities include group billings and scheduling.
IGAL SEBAG MD
- Invited speaker. Cardiology Rounds, Centre Hospitalier de l’Universite de Montreal. Pavillon Saint
Luc, Universite de Montreal. “Clinical Applications of Real-Time, Three Dimensional
Echocardiography. May 2006
- Invited speaker. Second Annual Symposium of Echocardiography, Hopital Sacre Coeur de Montreal.
“3-D and 4-D Echo: Ready for Clinical Use?” November 2005
RICHARD SHEPPARD MD

- McGill Medical School Admissions Committee April 2005
- Member of the Research Ethics Committee

JUDITH THERRIEN MD
- Invited speaker. First Annual Toronto International Symposium on Contemporary Questions in Heart
Disease. “When Should a Systemic Right Ventricle be put back in the Pulmonary Circuit”. Toronto
June 2005.
- Invited speaker. Fourth Cardiovascular Pediatric World Congress. “Patients with CCTGA and
moderate LAVVR should Undergo Surgery”. Buenos Aires, Argentina. September 2005.
- Invited speaker. “New Challenges posed by the Adult with Congenital Heart Disease”. Annual Saul
Mortimer Lecture, Montreal Children’s Hospital. December 2005.
Member of the Evaluation Board for the Cardiovascular Disorders Faculty of the Faculty of 1000
Medicine. 2005
- Reviewer for Circulation, JACC, American Journal of Cardiology, International Journal of
Cardiology, Cardiology in the Young, Expert Review of Cardiovascular Therapy, Congenital Heart
Disease Journal. 2003 -
Reviewer for Heart and Stroke grant. 2003 -
ANN WALLING MD
- Invited speaker. Clinical Case Scenarios. Preparation for Royal College Exams. McGill Academic
half day for Cardiology Residents. September 2005
- Invited speaker. Review of ACS exam. McGill Academic half day for Cardiology Residents.
December 2005
- Invited speaker. Review of AS/AR exam. McGill Academic half day for Cardiology Residents.
February 2006
- Invited speaker. Endocrinology Rounds JGH. CAD screening in diabetics March 2006
- Invited speaker. Review of MS/MR/RF exam. McGill Academic half day for Cardiology Residents.
May 2006
- Review of pericardial and Cardiomyopathy exams. McGill Academic half day for Cardiology
Residents.
- Invited speaker
Consulting Activities
RICHARD SHEPPARD MD
Consultant for Ortho-Biotech (Private Sector) regarding medical therapy for acute and chronic heart
failure therapies.
ANN WALLING MD
- Presented one talk sponsored by Merck
- Participated on one advisory board for Merck
Research Activities
MARK EISENBERG MD
-Co-investigator, Fonds de la Recherche en Santé du Quebec, Recherche evaluative et economique
portant sur la prevention primaire, la prevention secondaire et le traitement des maladies
cardiovasculaires. Principal Investigator - Stephane Rinfret. 2005 - 2006. $253,000.00
- Principal Investigator, Canadian Institutes of Health Research. A hierarchical-Bayesian met-analysis
of randomized clinical trials of smoking cessation aids. 2005-2006. $41,000.00
-Principal Investigator. Canadian Tobacco Control Research Initiative. The safety of transdermal
nicotine immediately following an acute coronary syndrome: The STADIA Trial Pilot Study. 2005-
2008. $50,000.00
-Co-Investigator, Canadian Institutes of Health Research. Gender and sex determinants of
cardiovascular disease: from bench to beyond. Principal Investigator: Louise Pilote. 2004-2008.
$1,5000,000.00
-Principal Investigator, Heart and Stroke Foundation of Canada. Zyban as an effective smoking
cessation aid for patients following ACS: The ZESCA trial. 2004-2007. $75,000.00.
-Co-investigator, Canadian Institutes of Health Research. Modern statistical methods to analyse
administrative databases. Principal Investigator: Louise Pilote. 2004-2007. $220,875.00.
-Co-Investigator, Canadian Institutes of Health Research. A population-based analysis of the
effectiveness and determinants of use of cardiac drugs for congestive heart failure. Principal
Investigator: Louise Pilote. 2004-2007. $365,538.00.
-Co-Investigator, Heart and Stroke Foundation of Canada. Early versus late coronary artery bypass
grafting after myocardial infarction. Principal Investigator: Lawrence Rudski. 2004-2007. $63,000.00.
-Principal Investigator, Canadian Tobacco Control Research Initiative. Post-Angiographic Rates of
Abstinence with Multiple Smoking Cessation Aids: The PROMISE Trial Pilot Study. 2004-2006.
$50,000.00.
-Principal Investigator, Canadian Institutes of Health Research. $1,470,000.00. Zyban as an Effective
Smoking Cessation Aid (ZESCA) trial. 2003 - 2008. $1,470,000.00
-Principal Investigatory, Aventis Pharma Inc.CABG Meds study - Perioperative Cardiac Medical
Therapy among Patients Undergoing Coronary Artery Bypass Graft Surgery. 2005-2006. $65,000.00.
GEORGE HONOS MD
- Boeringer. ONTARGET/TRANSCENT Trial. $4000.00/patient. 2002 -
- ASTRA. ASTRONOMER Study. $5000.00/patient. 2003 -
- BMS. ACTIVe Study/ $5000.00/patient. 2003 -
- Novartis. VALIDD Study. $5000.00/patient. 2005 -
DAVID LANGLEBEN MD
“Pathogenesis of Pulmonary Hypertension”, Canadian Institutes for Health Research, 2004-2007
“Angiogenic Growth Factor in Pulmonary Hypertension” Protocol XX99--10-049
“Pharmacogenomics of Pulmonary Arterial Hypertension”
"A Randomized, Double Blind Placebo Controlled Phase 3 Study of the phosphodiesterase
Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial
Hypertension" Protocol LVGY
"A Double-Blind, Extension Study to Evaluate the Long-Term Safety and Efficacy of the
Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with
Pulmonary Arterial Hypertension"
“An Open Label Extension Trial to Evaluate the Long Term Safety of Sitaxsentan Sodium
Treatment in Patients with Pulmonary Arterial Hypertension” Protocol FPH01-XC
“FPH02-X An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium
Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension”
FPH03: “A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium
Treatment in Patients with Pulmonary Arterial Hypertension”
Protocol A1481153. "A multi-centre, multinational, long -term, open-label extension study to
assess the safety of subject optimized treatment regimens of oral sildenafil when used in
combination with intravenous prostacyclin (epoprostenol), for pulmonary arterial hypertension in
subjects who have completed Study A1481141"
Protocol A1481141 “A Multinational, multi-center, randomized, double-blind, placebo-controlled,
parallel group study to assess the safety and efficacy of a subject optimized dose of sildenafil
(20,40, or 80 mg sildenafil tid) based on toleration, when used in combination with intravenous
prostacyclin (epoprostenol) in the treatment of pulmonary arterial hypertension.”
Genex-submax: “The Impact of Genetic Polymorphisms on Submaximal Exercise in Patients
with Heart Failure”
“Genetic Modulation of Left Ventricular Recovery in Recent Onset Cardiomyopathy”
“The Impact of Transforming Growth Factor Beta on Left Ventricular Remodeling Post-
Myocardial Infarction”
TDE-PH-301: “A 16 Week, International, Multicenter, Double-Blind, Randomized, Placebo-
Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets In
Combination with an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor in
Subjects with Pulmonary Arterial Hypertension”
TDE-PH-302 “A 12 Week, International, Multicenter, Double-Blind, Randomized, Placebo-
Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in
Subjects with Pulmonary Arterial Hypertension”
TDE-PH-304 “An Open-Label Extension Trial of UT-15C in Subjects with Pulmonary Arterial
Hypertension”
CAROLINE MICHEL MD
- Active Industry Grants. Vasogen: ACCLAIM Trial $5000.00/patient: 2003 - present
- Co-Investigator. ACCESS-CLINIC (Assess et prese en charge par les cliniques specialisees en
insuffisance cardiaque: $75000.00
Coapplicants - Louise Pilote, Nadia Giannetti, Eduard Beck, Marc Frenette Co-investigator. ACCESS-URG (Etude du suivi des patients vus en urgence hospitaliere pour insuffisance cardiaque). $75000.00 Principal Applicants- Louise Pilote and Debbie Feldman Coapplicants - Richard Sheppard, Stephanie Houde, Marc Frenette
RICHARD SHEPPARD MD
- IMAC study (NIH funded study based in Pittsburgh) Study of Genetics of Left Ventricular Recovery
- Principal Applicant Dennis McNamara (University of Pittsburgh Medical Center UPMC) - NIH funded - Operating funds received by UPMC via NIH: $3094.00 (awaiting funds for 3 more patients we have enrolled) - Access - Urgence (Study looking at CHF Clinic Patients in the ER) - Principal Investigator Louise Pilote at the MUHC - Funded by CIHR - $25000.00 per site (JGH is one of 3 sites) - Presentation of abstract Canadian Cardiovascular Conference in October 2005
- Member of Pulmonary Vascular Disease Research Group at the JGH, seeing patients (clinical visits
related to research) for protocols regarding pulmonary hypertension.
Publications 2005
Dr Mark Eisenberg
Bestawros A, Filion KB, Haider S, Pilote L, Eisenberg MJ. Coronary artery bypass graft surgery: do
women cost more? Can J Cardiol. 2005 Nov;21 (13): 1195-200.
Gitman MR, Okrainec K, Nguyen H, Duerr R, Del Core M, Fourchy D, Huynh T, Lader E, Rogers FJ,
Chaudry MR, Pilote L, Eisenberg MJ; ROSETTA-CABG Registry. Can J Cardiol. 2005
Nov;2121(13):1169-74.
Quon BS, First R, Eisenberg MJ. A comparison of brand-name drug prices between Canadian-based
Internet pharmacies and major US drug chain pharmacies. Ann Intern Med. 2005 Sep 20;143(6):397-
403.
Derghazarian, S. Eisenberg MJ. Late thrombosis associated with drug-eluting stents. Am Heart Hosp
J. 2005 Summer;3(3): 203-4.
Martineau P, Filion KB, Huk OL, Zukor DJ, Eisenberg MJ, Antoniou J. Primary hip arthroplasty
costs are greater in low-volume than in high-volume Canadian hospitals. Clin Orthop Relat Res.2005
Aug;(437):152-6.
Eisenberg MJ, Filion KB, Azoulay A, Brox AC, Haider S, Pilote L. Outcomes and cost of coronary
artery bypass graft surgery in the United States and Canada. Arch Intern Med. 2005 Jul
11;165(13):1506-13.
Eisenberg MJ, Ludvig J, Miner B. Smoking cessation in patients with coronary artery disease. Am
Heart J. 2005 Apr;149(4):565-72.
Eisenberg MJ, Teng FF, Chaudry MR, Ortiz J, Soblowski W, Ebrahim I, Saligrama RS, Serio K,
Lader E, Pilote L; NQWMI Investigators. Impact of invasive management versus noninvasive
management on functional status and quality of life following non Q-wave myocardial infarction: a
randomized clinical trial. Am Heart J. 2005 May;149(5):913–9.
Beck CA, Eisenberg MJ, Pilote L. Invasive versus noninvasive management of ST-elevation acute
myocardial infarction: a review of clinical trials and observational studies. Am Heart J.2005
Feb;149(2):194-9.
Saririan M, Cugno S, Blankenship J, Huyth T, Sedlis S, Sarling M, Pilote L, Wilson B, Eisenberg MJ.
Routine versus selective functional testing after percutaneous coronary intervention in patients with
diabetes mellitus. J Invasive Cardiol.2005 Jan;17(1):25-9.
Burelsy K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of
aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial
infarction. Arch Intern Med.2005 Apr 11;165(7):784-9.
Gioia LC, Filion KB, Haider S, Pilote L, Eisenberg MJ. Hospital readmissions following abdominal
aortic aneurysm repair. Ann Vasc Surg.2005 Jan;19(1):35-41.
Okrainec K, Platt R, Pilote L, Eisenberg MJ. Cardiac medical therapy in patients after undergoing
coronary artery bypass graft surgery: a review of randomized controlled trials. J Am Coll Cardiol. 2004
Jan 18;45(2):177-84.
Dr George Honos
Hemmelgam BR, McAlliser FA, Myers MG, McKay DW, Bolli P, Abbott C, Schiffrin EL, Grover S,
Honos G, Lebel M, Mann K, Wilson T, Penner B, Tremblay G, Tobe SW, Feldman RD for the
Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program
recommendations for the management of hypertension: Part 1 - Blood pressure measurement, diagnosis
and assessment of risk. Can J Cardiol 2005;21:645-656
Khan NA, et al for the Canadian Hypertension Education Program. The 2005 Canadian
Recommendations for the Management of Hypertension: Part II - Therapy. Can J Cardiol
2005;21:657-672.
Sanfilippo A. (chair), et al. Guidelines for the provision of echocardiography in Canada:
Recommendations of a joint Canadian Cardiovascular Society/Canadian Society of Echocardiography
Consensus Panel. Can J Cardiol 2005;21(9):763-780.
Dr David Langleben
Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, Robbins IM, Shapiro S, Tapson VF,
Swicke D, DeMarco T, Schilz R, Rubenfire M, Barst RJ. The 6 min-walk (6MW) as an efficacy
endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vasc
Pharmacol 2005;43:36-39.
Dr Igal Sebag
Sebag IA, Handschumacher MD, Ichinose F, Morgan JG, Hataishi R, Rodrigues AC, Guerrero JL,
Steudel W, Raher MJ, Halper EF, Derumeaux G, Bloch KD, Picard MH, Scherrer-Crosbie M.
Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging:
comparison with hemodynamics and sonomicrometry. Circulation 2005;111:2611-2616.
Sebag IA, Morgan JG, Nesta F, Handschumacher MD, Marshall JE, Hung J, Picard MH, Levine RA.
Usefulness of three-dimensionally guided rapid, reproducible assessment of mitral stenosis using
matrix-array ultrasound. Am J Cardiol 2005;96:1151-1156.
Gyger M, Rosenberg,A, Shamy A, Hercz A, Caplan S, Sebag IA, Brisson Ml, Roy DC. Vascular leak
syndrome and serositis as an unusual manifestation of chronic graft-versus-host disease in
nonmyeloablative transplants. Bone Marrow Transplant 2005;35:201-203.
Dr Richard Sheppard
Sheppard R, Bedi M, Kubota T et al. “Myocardial expressions of Fas and recovery of left ventricular
function in patients with recent-onset Cardiomyopathy”. J Am Coll Cardiol 2005;46: 1036-1042
Blanchet M, Sheppard R, Racaine N et al. “Effects of angiotensin converting enzyme inhibitor plus
irbesartan on maximal and submaximal exercise capacity and neurohormonal activation in patients with
congestive heart failure”. Am Heart J 2005; 149:938 el - 7.
Dr Judith Therrien
Therrien J, Provost Y, Colman J, Webb GD. Normalization of Right Ventricular Volumes Following
Pulmonary Valve Replacement in Adults After Repair of Tetralogy of Fallot: an MRI study. Am J
Cardiol 2004;95:779-782.
Salehia O, Horlick E, Schwerzmann M, Haberer K, McLaughlin P, Siu SC, Webb G, Therrien J.
Improvements in Cardiac Form and Function Following Transcatheter Closure of Secundum Atrial
Septal Defects. J Am Coll Cardiol 2005;45:499-504.
Textbook. Gatzoulis MA, Swan L, Therrien J, Pantely GA. Adult Congenital Heart Disease: A
Practical Guide. BMJ Ed Blackwell, 2005.
Dr Ann Walling
Dorval JF, Anderson TA, Buithieu J, Chan S, Hutchison S, Huynh T, Jobin J, Lonn E, Poirier P, Title I,
Walling A, Thang T, Boudreau G, Charbonneau F, Genest J. Reaching recommended lip and blood
pressure targets with amplodipine/atorvasatin combination in patients with coronary heart disease. Am
J Cardiol 2005:95:249-253.

Source: http://jgh.ca/uploads/Medicine/divisionofcardiology_0506.pdf